

Resource Summary Report

Generated by [NIF](#) on Aug 8, 2026

Noxa antibody [114C307]

RRID:AB_300536

Type: Antibody

Proper Citation

Abcam Cat# ab13654, RRID:AB_300536

Antibody Information

URL: http://antibodyregistry.org/AB_300536

Proper Citation: Abcam Cat# ab13654, RRID:AB_300536

Target Antigen: Noxa antibody [114C307]

Host Organism: mouse

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Western Blot; Flow Cytometry; Flow Cyt, WB

Antibody Name: Noxa antibody [114C307]

Description: This monoclonal targets Noxa antibody [114C307]

Target Organism: mouse, human

Antibody ID: AB_300536

Vendor: Abcam

Catalog Number: ab13654

Record Creation Time: 20250820T025336+0000

Record Last Update: 20250820T144805+0000

Ratings and Alerts

No rating or validation information has been found for Noxa antibody [114C307].

No alerts have been found for Noxa antibody [114C307].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yao H, et al. (2023) A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis. Cell reports, 42(8), 112961.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell, 185(9), 1521.

Latif AL, et al. (2021) BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature communications, 12(1), 241.

Cornelis R, et al. (2020) Stromal Cell-Contact Dependent PI3K and APRIL Induced NF- κ B Signaling Prevent Mitochondrial- and ER Stress Induced Death of Memory Plasma Cells. Cell reports, 32(5), 107982.

Jin S, et al. (2020) 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(13), 3371.

Ogiwara H, et al. (2019) Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers. Cancer cell, 35(2), 177.

Liang L, et al. (2018) A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity. Cell chemical biology, 25(6), 761.

Pan R, et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer cell, 32(6), 748.